Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
A E Elia, S Lalli, M R Monsurrò, A Sagnelli, A C Taiello, B Reggiori, V La Bella, G Tedeschi, A Albanese, A E Elia, S Lalli, M R Monsurrò, A Sagnelli, A C Taiello, B Reggiori, V La Bella, G Tedeschi, A Albanese
Abstract
Background and purpose: Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced in the liver and used for treatment of chronic cholestatic liver diseases. Experimental studies suggest that TUDCA may have cytoprotective and anti-apoptotic action, with potential neuroprotective activity. A proof of principle approach was adopted to provide preliminary data regarding the efficacy and tolerability of TUDCA in a series of patients with amyotrophic lateral sclerosis (ALS).
Methods: As a proof of principle, using a double-blind placebo controlled design, 34 ALS patients under treatment with riluzole who were randomized to placebo or TUDCA (1 g twice daily for 54 weeks) were evaluated after a lead-in period of 3 months. The patients were examined every 6 weeks. The primary outcome was the proportion of responders [those subjects with improvement of at least 15% in the Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) slope during the treatment period compared to the lead-in phase]. Secondary outcomes included between-treatment comparison of ALSFRS-R at study end, comparison of the linear regression slopes for ALSFFRS-R mean scores and the occurrence of adverse events.
Results: Tauroursodeoxycholic acid was well tolerated; there were no between-group differences for adverse events. The proportion of responders was higher under TUDCA (87%) than under placebo (P = 0.021; 43%). At study end baseline-adjusted ALSFRS-R was significantly higher (P = 0.007) in TUDCA than in placebo groups. Comparison of the slopes of regression analysis showed slower progression in the TUDCA than in the placebo group (P < 0.01).
Conclusions: This pilot study provides preliminary clinical data indicating that TUDCA is safe and may be effective in ALS.
Trial registration: ClinicalTrials.gov NCT00877604.
Keywords: amyotrophic lateral sclerosis; cholic acids; tauroursodeoxycholic acid.
© 2015 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Figures
References
- Ince PG, Lowe J, Shaw PJ. Amyotrophic lateral sclerosis: current issues in classification, pathogenesis and molecular pathology. Neuropathol Appl Neurobiol 1998; 24: 104–117.
- Turner MR, Bowser R, Bruijn L, et al Mechanisms, models and biomarkers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2013; 14(Suppl. 1): 19–32.
- Cozzolino M, Ferri A, Valle C, Carri MT. Mitochondria and ALS: implications from novel genes and pathways. Mol Cell Neurosci 2013; 55: 44–49.
- Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose‐ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425–1431.
- Sreedharan J, Brown RH Jr. Amyotrophic lateral sclerosis: problems and prospects. Ann Neurol 2013; 74: 309–316.
- Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999; 159: 2647–2658.
- Amaral JD, Xavier JM, Steer CJ, Rodrigues CM. The role of p53 in apoptosis. Discov Med 2010; 9: 145–152.
- Amaral JD, Viana RJ, Ramalho RM, Steer CJ, Rodrigues CM. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res 2009; 50: 1721–1734.
- Rodrigues CM, Steer CJ. The therapeutic effects of ursodeoxycholic acid as an anti‐apoptotic agent. Expert Opin Investig Drugs 2001; 10: 1243–1253.
- Vaz AR, Cunha C, Gomes C, Schmucki N, Barbosa M, Brites D. Glycoursodeoxycholic acid reduces matrix metalloproteinase‐9 and caspase‐9 activation in a cellular model of superoxide dismutase‐1 neurodegeneration. Mol Neurobiol 2014; PMID: 24848512 [Epub ahead of print].
- Schmidt B. Proof of principle studies. Epilepsy Res 2006; 68: 48–52.
- Leigh PN, Swash M, Iwasaki Y, et al Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5: 84–98.
- Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000; 1: 293–299.
- Andersen PM, Abrahams S, Borasio GD, et al EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol 2012; 19: 360–375.
- Gordon PH, Miller RG, Moore DH. ALSFRS‐R. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5(Suppl. 1): 90–93.
- Kimura F, Fujimura C, Ishida S, et al Progression rate of ALSFRS‐R at time of diagnosis predicts survival time in ALS. Neurology 2006; 66: 265–267.
- Jenkinson C, Hobart J, Chandola T, Fitzpatrick R, Peto V, Swash M. Use of the short form health survey (SF‐36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions. J Neurol 2002; 249: 178–183.
- Winhammar JM, Rowe DB, Henderson RD, Kiernan MC. Assessment of disease progression in motor neuron disease. Lancet Neurol 2005; 4: 229–238.
- Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV. Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002; 25: 709–714.
- Crosignani A, Battezzati PM, Setchell KD, et al Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose−response study. Dig Dis Sci 1996; 41: 809–815.
- Larghi A, Crosignani A, Battezzati PM, et al Ursodeoxycholic and tauro‐ursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Aliment Pharmacol Ther 1997; 11: 409–414.
- Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585–591.
- Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012; 3: CD001447.
- Cedarbaum JM, Stambler N, Malta E, et al The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13–21.
- Czaplinski A, Yen AA, Appel SH. Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J Neurol Neurosurg Psychiatry 2006; 77: 390–392.
- Mitsumoto H, Brooks BR, Silani V. Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved? Lancet Neurol 2014; 13: 1127–1138.
- Miller RG, Moore DH, Jackson CE. Western ALS Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5(Suppl. 1): 121–124.
- Min JH, Hong YH, Sung JJ, Kim SM, Lee JB, Lee KW. Oral solubilized ursodeoxycholic acid therapy in amyotrophic lateral sclerosis: a randomized cross‐over trial. J Korean Med Sci 2012; 27: 200–206.
- Ramalho RM, Viana RJ, Low WC, Steer CJ, Rodrigues CM. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol Med 2008; 14: 54–62.
- Shacka JJ, Roth KA. Regulation of neuronal cell death and neurodegeneration by members of the Bcl‐2 family: therapeutic implications. Curr Drug Targets CNS Neurol Disord 2005; 4: 25–39.
Source: PubMed